(AZN) AstraZeneca - Overview
Sector: Healthcare | Industry: Drug Manufacturers - General | Exchange: NYSE (USA) | Market Cap: 287.419m USD | Total Return: 30.8% in 12m
Avg Turnover: 355M
EPS Trend: 86.8%
Qual. Beats: 0
Rev. Trend: 99.2%
Warnings
Below Avwap Earnings
Tailwinds
No distinct edge detected
AstraZeneca PLC is a global biopharmaceutical company headquartered in Cambridge, UK, specializing in the discovery and commercialization of prescription medicines. Its portfolio targets oncology, cardiovascular, renal, metabolism, respiratory, immunology, and rare diseases. The company operates through a global distribution network serving primary and specialty care physicians.
The business model relies heavily on high-margin intellectual property protected by patents and a robust R&D pipeline to offset the impact of generic competition. Within the pharmaceutical sector, companies like AstraZeneca increasingly utilize strategic collaborations and AI-driven multimodal models to accelerate drug discovery and development cycles.
For a deeper analysis of these market dynamics, you may wish to explore the data tools at ValueRay.
- Oncology portfolio revenue scales through Tagrisso and Enhertu market expansion
- Rare disease segment growth accelerates via Alexion integration and pipeline
- Emerging markets exposure drives volume growth despite pricing pressure in China
- Research and development productivity maintains competitive advantage in high-margin biologics
| Net Income: 10.4b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -1.12 > 1.0 |
| NWC/Revenue: -4.89% < 20% (prev -5.44%; Δ 0.55% < -1%) |
| CFO/TA 0.13 > 3% & CFO 14.3b > Net Income 10.4b |
| Net Debt (28.1b) to EBITDA (20.5b): 1.37 < 3 |
| Current Ratio: 0.91 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.56b) vs 12m ago 0.0% < -2% |
| Gross Margin: 81.68% > 18% (prev 81.39%; Δ 0.29% > 0.5%) |
| Asset Turnover: 54.88% > 50% (prev 51.75%; Δ 3.13% > 0%) |
| Interest Coverage Ratio: 8.43 > 6 (EBIT TTM 14.7b / Interest Expense TTM 1.74b) |
| A: -0.03 (Total Current Assets 29.6b - Total Current Liabilities 32.6b) / Total Assets 114b |
| B: 0.08 (Retained Earnings 9.67b / Total Assets 114b) |
| C: 0.13 (EBIT TTM 14.7b / Avg Total Assets 110b) |
| D: 0.71 (Book Value of Equity 47.3b / Total Liabilities 66.6b) |
| Altman-Z'' = 1.75 = BBB |
| DSRI: 0.97 (Receivables 14.1b/13.2b, Revenue 60.4b/55.0b) |
| GMI: 1.00 (GM 81.39% / 81.68%) |
| AQI: 0.95 (AQ_t 0.61 / AQ_t-1 0.64) |
| SGI: 1.10 (Revenue 60.4b / 55.0b) |
| TATA: -0.03 (NI 10.4b - CFO 14.3b) / TA 114b) |
| Beneish M = -3.01 (Cap -4..+1) = AA |
As of June 06, 2026, the stock is trading at USD 185.95 with a total of 2,188,448 shares traded.
Over the past week, the price has changed by +0.15%,
over one month by +2.60%,
over three months by -5.86% and
over the past year by +30.76%.
AstraZeneca has received a consensus analysts rating of 4.56. Therefore, it is recommended to buy AZN.
- StrongBuy: 6
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 224.5 | 20.7% |
P/E Trailing = 27.9532
P/E Forward = 18.2149
P/S = 4.7555
P/B = 6.0723
P/EG = 1.4349
Revenue TTM = 60.4b USD
EBIT TTM = 14.7b USD
EBITDA TTM = 20.5b USD
Long Term Debt = 24.5b USD (from longTermDebt, last quarter)
Short Term Debt = 7.96b USD (from shortTermDebt, last quarter)
Debt = 35.8b USD (from shortLongTermDebtTotal, last quarter) + Leases 1.89b
Net Debt = 28.1b USD (calculated: Debt 35.8b - CCE 7.67b)
Enterprise Value = 316b USD (287b + Debt 35.8b - CCE 7.67b)
Interest Coverage Ratio = 8.43 (Ebit TTM 14.7b / Interest Expense TTM 1.74b)
EV/FCF = 34.64x (Enterprise Value 316b / FCF TTM 9.11b)
FCF Yield = 2.89% (FCF TTM 9.11b / Enterprise Value 316b)
FCF Margin = 15.07% (FCF TTM 9.11b / Revenue TTM 60.4b)
Net Margin = 17.19% (Net Income TTM 10.4b / Revenue TTM 60.4b)
Gross Margin = 81.68% ((Revenue TTM 60.4b - Cost of Revenue TTM 11.1b) / Revenue TTM)
Gross Margin QoQ = 82.48% (prev 79.89%)
Tobins Q-Ratio = 2.77 (Enterprise Value 316b / Total Assets 114b)
Interest Expense / Debt = 4.85% (Interest Expense 1.74b / Debt 35.8b)
Taxrate = 19.52% (2.52b / 12.9b)
NOPAT = 11.8b (EBIT 14.7b * (1 - 19.52%))
Current Ratio = 0.91 (Total Current Assets 29.6b / Total Current Liabilities 32.6b)
Debt / Equity = 0.76 (Debt 35.8b / totalStockholderEquity, last quarter 47.3b)
Debt / EBITDA = 1.37 (Net Debt 28.1b / EBITDA 20.5b)
Debt / FCF = 3.09 (Net Debt 28.1b / FCF TTM 9.11b)
Total Stockholder Equity = 46.7b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.43% (Net Income 10.4b / Total Assets 114b)
RoE = 22.27% (Net Income TTM 10.4b / Total Stockholder Equity 46.7b)
RoCE = 20.61% (EBIT 14.7b / Capital Employed (Equity 46.7b + L.T.Debt 24.5b))
RoIC = 13.65% (NOPAT 11.8b / Invested Capital 86.4b)
WACC = 6.44% (E(287b)/V(323b) * Re(6.76%) + D(35.8b)/V(323b) * Rd(4.85%) * (1-Tc(0.20)))
Discount Rate = 6.76% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 22.68 | Cagr: 0.0%
[DCF] Terminal Value 74.60% ; FCFF base≈9.34b ; Y1≈8.91b ; Y5≈8.53b
[DCF] Fair Price = 68.40 (EV 134b - Net Debt 28.1b = Equity 106b / Shares 1.55b; r=8.35% [WACC [floored]]; 5y FCF grow -5.88% → 2.50% )
EPS Correlation: 86.78 | EPS CAGR: 12.55% | SUE: 0.08 | # QB: 0
Revenue Correlation: 99.23 | Revenue CAGR: 12.92% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.27 | Chg30d=+0.21% | Revisions=-33% | Analysts=2
EPS next Quarter (2026-09-30): EPS=1.31 | Chg30d=-2.09% | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=6.84 | Chg30d=+31.50% | Revisions=+0% | GrowthEPS=+49.3% | GrowthRev=+7.8%
EPS next Year (2027-12-31): EPS=8.02 | Chg30d=+0.95% | Revisions=-33% | GrowthEPS=+17.3% | GrowthRev=+6.0%
[Analyst] Revisions Ratio: -33%